Form 4: PROCEPT BioRobotics Corp: Director Acquires Shares and Options

Director Taylor C. Harris acquired 3,315 shares of common stock and was granted 5,853 stock options in PROCEPT BioRobotics Corp.

Summary

• Director Taylor C. Harris acquired 3,315 shares of PROCEPT BioRobotics Corp. common stock on June 9, 2026.
• The acquisition of common stock was valued at $0, indicating it was likely a grant or award.
• Harris also received a stock option grant for 5,853 shares on June 9, 2026, with an exercise price of $28.78.
• Both the restricted stock units (RSUs) and the stock option vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports standard insider transactions related to compensation and does not provide new financial performance data or strategic shifts that would significantly alter the investment outlook.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• Granting of stock options aligns management incentives with shareholder value creation.
• Vesting conditions tied to continued service and annual meetings encourage long-term commitment.

Negatives

• The acquisition of common stock was at a price of $0, suggesting it was an award rather than an open market purchase, which provides less insight into market valuation confidence.

Risks

• The vesting of RSUs and stock options is contingent on continued service, meaning a departure before vesting would result in forfeiture.
• The stock option exercise price of $28.78 implies that the stock price needs to increase significantly for the options to be profitable.

Future Outlook

The future outlook is not directly addressed in this Form 4 filing, which primarily reports on insider transactions. However, the vesting conditions for RSUs and stock options suggest a focus on long-term employee retention and performance.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported in Form 4 filings, are closely watched by investors. Director Harris's acquisition of stock and options in PROCEPT BioRobotics Corp. is a standard compensation and incentive mechanism within the medical technology sector, aiming to align executive interests with shareholder returns.

Stakeholder Impact

• Shareholders: The acquisition of stock by a director may be viewed positively, suggesting confidence in the company's future. The alignment of incentives through stock options is also generally seen as beneficial for shareholders.
• Employees: The vesting conditions for RSUs and stock options are designed to retain key personnel, impacting employee morale and retention.
• Management: The filing details compensation elements for a director, which is a standard aspect of executive compensation.

Next Steps

• Vesting of RSUs and stock options on the earlier of the one-year anniversary of the grant date or the next annual meeting, subject to continued service.

Key Dates

Keywords

PROCEPT BioRobotics Corp, PRCT, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, SEC Filing, Beneficial Ownership